Dypiridamole is 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido [5,4-d]-pyrimidine compound, coronary vasodilator, which acts via adenosine. Its effect is on small vessels in the coronary territory and slightily  in the systemic circulation. Therefore, augments coronary flow up to 400%, with a mild diminution of blood pressure, mild heart rate increase and no oxygen consumption increment.

            It produces nausea, vomitus, dizziness and headache, which are easily controlled by aminophylline given intravenously.

References:

1 Beer SG, Heo J, Iskandrian AS. Dipyridamole thallium imaging. Am J Cardiol. 1991 May 21;67(14):18D-26D.

2 Fleming RM. High-dose dipyridamole and gated sestamibi SPECT imaging provide diagnostic resting and stress ejection fractions useful for predicting extent of coronary artery disease. Angiology. 2002 Jul-Aug;53(4):415-21.

Home     Index    Myocardial  Spect Thallium   Myocardial  Spect Mibi  Myocardial Pharmacologic Intervention